计量卡培他滨联合芳香化酶抑制剂治疗转移性激素受体阳性、HER2阴性乳腺癌症患者

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2019-11-01 DOI:10.2217/bmt-2019-0012

Bader A Abdelmaksoud, Mostafa Toam, A. Fayed

{"title":"计量卡培他滨联合芳香化酶抑制剂治疗转移性激素受体阳性、HER2阴性乳腺癌症患者","authors":"Bader A Abdelmaksoud, Mostafa Toam, A. Fayed","doi":"10.2217/bmt-2019-0012","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the efficacy and safety of combined metronomic capecitabine with aromatase inhibitors (AIs) for patients with newly diagnosed metastatic hormone-receptor positive, HER2-negative breast cancer. Patients & methods: A total of 41 women with a diagnosis of metastatic hormone-receptor positive, HER2-negative breast cancer received oral metronomic capecitabine, 500 mg/m2 twice daily combined with an AI. Results: After a median follow-up of 24 months (9–50), a median of 15 months of treatment were completed, the median time to progression was 15 months (12.6–17.3) and the median overall survival was 37 months (23.6–50.4). The treatment was tolerated with less than 10% grade 3 toxicities. Conclusion: Combination of metronomic capecitabine and AIs appears to be safe and has encouraging results in advanced hormone-receptor positive, HER2-negative breast cancer.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2019-0012","citationCount":"3","resultStr":"{\"title\":\"Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer\",\"authors\":\"Bader A Abdelmaksoud, Mostafa Toam, A. Fayed\",\"doi\":\"10.2217/bmt-2019-0012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: To evaluate the efficacy and safety of combined metronomic capecitabine with aromatase inhibitors (AIs) for patients with newly diagnosed metastatic hormone-receptor positive, HER2-negative breast cancer. Patients & methods: A total of 41 women with a diagnosis of metastatic hormone-receptor positive, HER2-negative breast cancer received oral metronomic capecitabine, 500 mg/m2 twice daily combined with an AI. Results: After a median follow-up of 24 months (9–50), a median of 15 months of treatment were completed, the median time to progression was 15 months (12.6–17.3) and the median overall survival was 37 months (23.6–50.4). The treatment was tolerated with less than 10% grade 3 toxicities. Conclusion: Combination of metronomic capecitabine and AIs appears to be safe and has encouraging results in advanced hormone-receptor positive, HER2-negative breast cancer.\",\"PeriodicalId\":43086,\"journal\":{\"name\":\"Breast Cancer Management\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2019-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/bmt-2019-0012\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/bmt-2019-0012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/bmt-2019-0012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 3

摘要

目的：评价节拍性卡培他滨联合芳香化酶抑制剂（AIs）治疗新诊断的转移性激素受体阳性、HER2阴性癌症患者的疗效和安全性。患者和方法：共有41名被诊断为转移性激素受体阳性、HER2阴性癌症的女性接受口服卡培他滨，500 mg/m2，每日两次，联合AI。结果：中位随访24个月（9-50）后，中位完成15个月的治疗，中位进展时间为15个月（12.6–17.3），中位总生存期为37个月（23.6–50.4）。该治疗具有耐受性，3级毒性低于10%。结论：节拍性卡培他滨和AIs联合治疗晚期激素受体阳性、HER2阴性的癌症是安全的，并取得了令人鼓舞的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer

Aim: To evaluate the efficacy and safety of combined metronomic capecitabine with aromatase inhibitors (AIs) for patients with newly diagnosed metastatic hormone-receptor positive, HER2-negative breast cancer. Patients & methods: A total of 41 women with a diagnosis of metastatic hormone-receptor positive, HER2-negative breast cancer received oral metronomic capecitabine, 500 mg/m2 twice daily combined with an AI. Results: After a median follow-up of 24 months (9–50), a median of 15 months of treatment were completed, the median time to progression was 15 months (12.6–17.3) and the median overall survival was 37 months (23.6–50.4). The treatment was tolerated with less than 10% grade 3 toxicities. Conclusion: Combination of metronomic capecitabine and AIs appears to be safe and has encouraging results in advanced hormone-receptor positive, HER2-negative breast cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.